Nancy Lin

Nancy Lin: Updated data for Pfizer cdk4-selective inhibitor PF-07220060

Nancy Lin, Associate Chief of Division of Breast Oncology at Susan F. Smith Center for Women’s Cancers, shared on X:

“Updated data for Pfizer cdk4-selective inhibitor PF-07220060.

  • patient population: 100% prior cdk4/6i
  • favorable tox profile
  • 32% ORR, median PFS 8.1 months
  • efficacy regardless of ESR1 and PIK3CA mutation status.”

cdk4-selective

Source: Nancy Lin/X

cancer CDK4 inhibitor CDK4/6i Nancy Lin OncoDaily Oncology PF-07220060 pfizer PIK3CA mutation Susan F. Smith Center for Women's Cancers